quartr
KYORIN Pharmaceutical: Profits dropped sharply on lower new drug sales and higher costs, but guidance is unchanged
Net sales and profits declined year-over-year due to lower new drug sales and NHI price revisions, despite growth in Beova and generics. Operating profit and net income fell sharply, but full-year forecasts and dividend plans remain unchanged.Original document: KYORIN Pharmaceutical Co.,Ltd. [4569…